Clinical case: Tirzepatide dose reduction and the impact on long-term maintenance of weight loss

Description

In this Quick Case, Endocrinologist A/Prof Samantha Hocking outlines evidence from the SURMOUNT-MAINTAIN study, demonstrating how tirzepatide dose reduction or elimination impacts the maintenance of weight loss, cardiometabolic benefits, and clinical decision-making in obesity management (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Gary Wittert

Prof Gary Wittert

The Peptide Craze – What You Need to Know

Prof Andrew Sindone AM

Prof Andrew Sindone AM

Managing Acute Heart Failure After Discharge: A Practical Guide for GPs

A/Prof Gino Pecoraro OAM

A/Prof Gino Pecoraro OAM

Oral Contraceptives on the PBS – A Practical Guide for GPs

Dr Terri Foran

Dr Terri Foran

The Impact of PFAS & Other Endocrine Disrupting Chemicals on Fertility

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

A/Prof Samantha Hocking

expert

A/Prof Samantha Hocking

Endocrinologist; Royal Prince Alfred Hospital; Clinical Academic at Charles Perkins Research Centre, University of Sydney; President, National Association of Clinical Obesity Services (NACOS)

Date published: 17 July 2026